Skip to content

Long-term Neurovascular Complications After Radiation Therapy in Head and Neck Cancer

The Ambidirectional Cohort Study of Neurovascular Complications After Radiation Therapy in Head and Neck Cancer Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06111430
Enrollment
800
Registered
2023-11-01
Start date
2022-04-11
Completion date
2026-04-10
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurovascular Complications, Radiation Treatment

Brief summary

Head and neck cancer is a group of cancers develop from the soft tissues, salivary gland, mucosa of the upper respiratory or digestive system covering the oral and nasal cavity. Radiotherapy is usually the standard treatment of Head and neck cancers. In the present study, investigators aim to study the prevalence of cervical-cranial vascular complications during the early stages in these Head and neck cancer patients receiving Radiotherapy. Investigators will also compare the results between Nasopharyngeal cancer and other Head and neck cancerpatients receiving Radiotherapy.

Interventions

None listed

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

Population: Prospective cohort Inclusion Criteria: 1. Age ≥20 years. 2. Head and neck cancer patient . 3. Had ever received radiation therapy (RT) ≦ 72 months before inclusion in the registry. 4. Had ≥ 1 brain images and cervical-cranial vascular studies between the end of RT and d date of enrolment.

Exclusion criteria

1. Age \<20 years. 2. Patients not willing to sign the informed consent. Population: Retrospective validation cohort Inclusion Criteria: 1. Age ≥20 years. 2. Head and neck cancer patient. 3. Had ever received radiation therapy (RT) \> 120 months before the adoption date of IRB at the participant site. 4. Had ≥ 2 brain images and cervical-cranial vascular studies between the end of RT and 6\~10 years after RT, one within 5 years after RT, the other after 5 years after RT.

Design outcomes

Primary

MeasureTime frameDescription
Significant CAS at internal carotid artery or common carotid artery1 yearWe define significant CAS as (a) \>50% stenosis on the B-mode with peak systolic velocities ≥120 cm/s based on the hemodynamic criteria at any internal carotid artery or common carotid artery in the CDU study according to the standard ultrasound criteria35; or (b) \> 50% diameter stenosis on the follow up CT or MR images.
Cerebral infarctions (CI)1 yearThe CI is defined whenever there were symptomatic IS occurrence of presence of asymptomatic IS on the reviewed brain MRIs.
Significant extracranial vertebral artery stenosis (VAS)1 year\> 50% diameter stenosis on the follow up CT or MR images.
Significant intracranial artery stenosis1 yearPresence of \> 50% stenosis at intracranial ICA/VA, basilar artery, middle cerebral artery, anterior cerebral artery, or anterior cerebral artery.
Presence of carotid blow-out syndrome1 yearCarotid blow out syndrome was categorized as type 1 (threaten type), type 2 (impending blowouts), and type 3 (acute CBS hemorrhage).
Presence of TLN1 yearWe will identify white matter lesions, contrast-enhanced lesions, Cysts, and local mass effect. The white matter lesions in the temporal lobe will be divided into three groups: mild (small focal areas), moderate (larger confluent areas) and severe (large confluent areas extending outside the radiation field with or without local mass effect). The cysts will be evaluated for size and number. The local mass effect will be classified as mild (affecting only the temporal lobe sulci), moderate (affecting the sulci and ventricles) and severe (affecting the midline of the brain).
Presence of hypothyroidism1 yearClinical hypothyroidism was diagnosed when a patient had free T4 ≤ 0.80 ng/dL with elevated TSH (\>5.0 mU/L).
Tumor recurrence1 yearRelapse
Mortality1 yearDeath

Countries

Taiwan

Contacts

CONTACTChi-Hung Liu
ivanliu001@cgmh.org.tw(03)3281200
CONTACTHui-Ching Kang
karen0201kang@gmail.com(03)3281200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026